title: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma.
abstract: Malignant gliomas are the most common and deadly brain tumors. Nevertheless, survival for patients with glioblastoma, the most aggressive glioma, although individually variable, has improved from an average of 10 months to 14 months after diagnosis in the last 5 years due to improvements in the standard of care. Radiotherapy has been of key importance to the treatment of these lesions for decades, and the ability to focus the beam and tailor it to the irregular contours of brain tumors and minimize the dose to nearby critical structures with intensity-modulated or image-guided techniques has improved greatly. Temozolomide, an alkylating agent with simple oral administration and a favorable toxicity profile, is used in conjunction with and after radiotherapy. Newer surgical techniques, such as fluorescence-guided resection and neuroendoscopic approaches, have become important in the management of malignant gliomas. Furthermore, new discoveries are being made in basic and translational research, which are likely to improve this situation further in the next 10 years. These include agents that block 1 or more of the disordered tumor proliferation signaling pathways, and that overcome resistance to already existing treatments. Targeted therapies such as antiangiogenic therapy with antivascular endothelial growth factor antibodies (bevacizumab) are finding their way into clinical practice. Large-scale research efforts are ongoing to provide a comprehensive understanding of all the genetic alterations and gene expression changes underlying glioma formation. These have already refined the classification of glioblastoma into 4 distinct molecular entities that may lead to different treatment regimens. The role of cancer stem-like cells is another area of active investigation. There is definite hope that by 2020, new cocktails of drugs will be available to target the key molecular pathways involved in gliomas and reduce their mortality and morbidity, a positive development for patients, their families, and medical professionals alike.
authors.affiliation: Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA. evanmei@emory.edu
authors.forename: Erwin G
authors.initials: EG
authors.lastname: Van Meir
authors.forename: Costas G
authors.initials: CG
authors.lastname: Hadjipanayis
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Norden
authors.forename: Hui-Kuo
authors.initials: HK
authors.lastname: Shu
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Olson
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D014408:Biomarkers, Tumor; D001932:Brain Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D004815:Epidermal Growth Factor / Q000187:drug effects; D005909:Glioblastoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008967:Molecular Biology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D015398:Signal Transduction; D017211:Treatment Failure; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D042461:Vascular Endothelial Growth Factor A; D004815:Epidermal Growth Factor; D040262:Receptors, Vascular Endothelial Growth Factor
references.citation: J Natl Cancer Inst. 2009 Apr 1;101(7):450-1
references.pmid: 19318637
references.citation: J Clin Oncol. 2009 Feb 10;27(5):740-5
references.pmid: 19114704
references.citation: Semin Radiat Oncol. 2005 Jul;15(3):192-201
references.pmid: 15983944
references.citation: Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1397-404
references.pmid: 12459362
references.citation: Curr Opin Neurol. 2008 Dec;21(6):728-35
references.pmid: 18989120
references.citation: J Clin Oncol. 2009 Oct 1;27(28):4733-40
references.pmid: 19720927
references.citation: Curr Opin Investig Drugs. 2006 Dec;7(12):1067-76
references.pmid: 17209524
references.citation: PLoS Med. 2008 Jan 22;5(1):e8
references.pmid: 18215105
references.citation: Neurosurgery. 2008 Mar;62(3 Suppl 1):51-5; discussion 55-6
references.pmid: 18424967
references.citation: Nature. 1985 Jan 10-18;313(5998):144-7
references.pmid: 2981413
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4722-9
references.pmid: 17947719
references.citation: J Cancer Res Clin Oncol. 2009 Sep;135(9):1239-44
references.pmid: 19277712
references.citation: Lancet Oncol. 2006 May;7(5):392-401
references.pmid: 16648043
references.citation: Oncogene. 2007 Aug 16;26(38):5577-86
references.pmid: 17369861
references.citation: Acta Neurochir Suppl. 2003;88:169-77
references.pmid: 14531575
references.citation: J Exp Med. 1997 Oct 20;186(8):1201-12
references.pmid: 9334359
references.citation: Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69
references.pmid: 15094120
references.citation: Science. 2007 Oct 12;318(5848):287-90
references.pmid: 17872411
references.citation: Clin Cancer Res. 2007 May 1;13(9):2728-37
references.pmid: 17473206
references.citation: J Mol Med (Berl). 2009 Apr;87(4):363-74
references.pmid: 19189072
references.citation: Clin Cancer Res. 2009 May 15;15(10):3617-23
references.pmid: 19417015
references.citation: Cancer Res. 1992 Aug 15;52(16):4297-305
references.pmid: 1643627
references.citation: Cancer Cell. 2010 Jan 19;17(1):98-110
references.pmid: 20129251
references.citation: J Natl Cancer Inst. 2005 Jun 15;97(12):880-7
references.pmid: 15956649
references.citation: Clin Cancer Res. 2006 Nov 1;12(21):6331-6
references.pmid: 17085642
references.citation: Neurosurgery. 2006 Feb;58(1 Suppl):ONS166-9; discussion ONS166-9
references.pmid: 16543875
references.citation: Br J Cancer. 2003 Apr 7;88(7):1004-11
references.pmid: 12671695
references.citation: J Nucl Med. 1999 Feb;40(2):331-8
references.pmid: 10025843
references.citation: Trends Mol Med. 2009 Nov;15(11):519-30
references.pmid: 19889578
references.citation: Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31
references.pmid: 231022
references.citation: Science. 2008 Sep 26;321(5897):1807-12
references.pmid: 18772396
references.citation: Nature. 2008 Oct 23;455(7216):1129-33
references.pmid: 18948956
references.citation: N Engl J Med. 2005 Mar 10;352(10):997-1003
references.pmid: 15758010
references.citation: Cancer. 2005 Nov 15;104(10):2168-73
references.pmid: 16220556
references.citation: Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1147-52
references.pmid: 15001257
references.citation: Cancer Res. 2000 Sep 15;60(18):5143-50
references.pmid: 11016641
references.citation: J Nucl Med. 2006 Mar;47(3):410-8
references.pmid: 16513609
references.citation: FASEB J. 2004 Feb;18(2):338-40
references.pmid: 14657001
references.citation: Cancer Cell. 2007 Jan;11(1):83-95
references.pmid: 17222792
references.citation: Neurosurgery. 2008 May;62(5 Suppl):A11-7; discussion A17-8
references.pmid: 18580775
references.citation: Cancer Cell. 2002 Apr;1(3):269-77
references.pmid: 12086863
references.citation: Neurosurgery. 1999 Apr;44(4):795-804; discussion 804-6
references.pmid: 10201305
references.citation: J Nucl Med. 2005 Jun;46(6):945-52
references.pmid: 15937304
references.citation: Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1246-53
references.pmid: 17967314
references.citation: Cancer Cell. 2004 Nov;6(5):507-16
references.pmid: 15542434
references.citation: Radiology. 1993 Jan;186(1):45-53
references.pmid: 8380108
references.citation: J Neurosurg. 2006 Aug;105(2):271-8
references.pmid: 17219833
references.citation: Cancer Cell. 2009 Mar 3;15(3):220-31
references.pmid: 19249680
references.citation: Invest New Drugs. 2005 Aug;23(4):357-61
references.pmid: 16012795
references.citation: Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):130-6
references.pmid: 20399036
references.citation: Nature. 2009 Dec 10;462(7274):739-44
references.pmid: 19935646
references.citation: Clin Cancer Res. 2006 May 1;12(9):2716-29
references.pmid: 16675563
references.citation: Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):588-94
references.pmid: 18565358
references.citation: J Clin Oncol. 2002 Mar 15;20(6):1635-42
references.pmid: 11896114
references.citation: J Immunol. 1992 May 15;148(10):3140-6
references.pmid: 1315829
references.citation: Int J Cancer. 1999 Feb 19;84(1):10-8
references.pmid: 9988225
references.citation: Nat Rev Cancer. 2008 Aug;8(8):604-17
references.pmid: 18497750
references.citation: Neuro Oncol. 2003 Apr;5(2):79-88
references.pmid: 12672279
references.citation: J Neurooncol. 2010 Jan;96(2):219-30
references.pmid: 19562254
references.citation: Ann Oncol. 2009 Sep;20(9):1596-1603
references.pmid: 19491283
references.citation: Neurosurgery. 2008 Apr;62(4):753-64; discussion 264-6
references.pmid: 18496181
references.citation: Cancer Chemother Pharmacol. 2010 Jan;65(2):353-61
references.pmid: 19499221
references.citation: Med Dosim. 2008 Winter;33(4):268-74
references.pmid: 18973853
references.citation: J Clin Oncol. 2005 Aug 10;23(23):5294-304
references.pmid: 15998902
references.citation: Clin Neurosurg. 2008;55:20-6
references.pmid: 19248665
references.citation: J Clin Oncol. 2009 Apr 20;27(12):2052-8
references.pmid: 19307505
references.citation: Cancer Res. 2009 Jul 1;69(13):5296-300
references.pmid: 19549889
references.citation: Cancer Res. 1990 Oct 15;50(20):6683-8
references.pmid: 2208133
references.citation: J Neurosurg. 1999 Aug;91(2):251-60
references.pmid: 10433313
references.citation: Neurology. 2009 Apr 7;72(14):1217-22
references.pmid: 19349600
references.citation: Proc Natl Acad Sci U S A. 1989 Apr;86(8):2858-62
references.pmid: 2565039
references.citation: Acta Oncol. 2009;48(1):52-8
references.pmid: 19031176
references.citation: Nature. 2006 Dec 21;444(7122):1032-7
references.pmid: 17183313
references.citation: Nat Rev Neurosci. 2007 Aug;8(8):610-22
references.pmid: 17643088
references.citation: Clin Cancer Res. 2006 Aug 15;12(16):4899-907
references.pmid: 16914578
references.citation: J Neurooncol. 2009 Feb;91(3):329-36
references.pmid: 18953493
references.citation: Med Dosim. 2003 Winter;28(4):261-5
references.pmid: 14684191
references.citation: N Engl J Med. 2008 Jul 31;359(5):492-507
references.pmid: 18669428
references.citation: Small. 2008 Nov;4(11):1925-9
references.pmid: 18752211
references.citation: Lancet. 2002 Mar 23;359(9311):1011-8
references.pmid: 11937180
references.citation: J Clin Oncol. 2006 Aug 1;24(22):3651-6
references.pmid: 16877733
references.citation: Neurol Clin. 2007 Nov;25(4):1005-33, ix
references.pmid: 17964024
references.citation: J Neurosurg. 2009 Jan;110(1):173-80
references.pmid: 18834263
references.citation: J Clin Oncol. 1999 Sep;17(9):2762-71
references.pmid: 10561351
references.citation: J Natl Cancer Inst. 1993 Nov 17;85(22):1836-9
references.pmid: 8230263
references.citation: Science. 2009 Apr 10;324(5924):261-5
references.pmid: 19359588
references.citation: Nature. 2008 Oct 23;455(7216):1061-8
references.pmid: 18772890
references.citation: Neurosurgery. 2008 Feb;62 Suppl 2:575-97; discussion 597-8
references.pmid: 18596446
references.citation: Neurology. 2008 Mar 4;70(10):779-87
references.pmid: 18316689
references.citation: Acta Neurochir (Wien). 2003 Jan;145(1):5-10
references.pmid: 12545256
references.citation: J Proteome Res. 2007 Feb;6(2):559-70
references.pmid: 17269713
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1268-74
references.pmid: 19204207
references.citation: Neurology. 2006 Apr 25;66(8):1258-60
references.pmid: 16636248
references.citation: J Clin Oncol. 2007 Jun 20;25(18):2601-6
references.pmid: 17577040
references.citation: N Engl J Med. 2005 Nov 10;353(19):2012-24
references.pmid: 16282176
references.citation: Am J Pathol. 2003 Apr;162(4):1083-93
references.pmid: 12651601
references.citation: Lancet. 1995 Apr 22;345(8956):1008-12
references.pmid: 7723496
references.citation: Science. 1999 Jun 18;284(5422):1994-8
references.pmid: 10373119
references.citation: Int J Radiat Oncol Biol Phys. 1986 Oct;12(10):1793-800
references.pmid: 3531110
references.citation: Oncogene. 2004 Jun 3;23(26):4594-602
references.pmid: 15077177
references.citation: Br J Cancer. 2000 Sep;83(5):588-93
references.pmid: 10944597
references.citation: Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10842-7
references.pmid: 9724792
references.citation: Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6712-8
references.pmid: 18006772
references.citation: Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60
references.pmid: 15465203
references.citation: Semin Radiat Oncol. 2009 Jul;19(3):171-8
references.pmid: 19464632
references.citation: Clin Cancer Res. 2009 Sep 1;15(17):5297-302
references.pmid: 19706811
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: Stereotact Funct Neurosurg. 1997;69(1-4 Pt 2):124-8
references.pmid: 9711744
references.citation: Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):47-55
references.pmid: 16111571
references.citation: Lab Invest. 2004 Apr;84(4):397-405
references.pmid: 14990981
references.citation: Int J Cancer. 1994 Jul 15;58(2):240-7
references.pmid: 7517920
references.citation: Neuro Oncol. 2010 Feb;12(2):116-21
references.pmid: 20150378